Intrahepatic and peripheral CXCL10 expression in hepatitis C virus-infected patients treated with telaprevir, pegylated interferon, and ribavirin

Marija Zeremski; Rositsa B. Dimova; Samantha Benjamin; Marina S. Penney; Martyn C. Botfield; Andrew H. Talal

doi:10.1093/infdis/jiu807

Intrahepatic and peripheral CXCL10 expression in hepatitis C virus-infected patients treated with telaprevir, pegylated interferon, and ribavirin

Marija Zeremski
, Rositsa B. Dimova
, Samantha Benjamin
, Marina S. Penney
, Martyn C. Botfield
, Andrew H. Talal

Medicine

SUNY Buffalo
Vertex Pharmaceuticals, Inc.

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

We assessed peripheral and liver CXCL10 levels in 15 patients treated with telaprevir/pegylated interferon/ribavirin. Induction of peripheral CXCL10 messenger RNA (mRNA) peaked (mean fold-induction [±SD], 3.1 ± 1.9) between treatment hour 6 and day 2, while induction of intrahepatic CXCL10 mRNA peaked (mean fold-induction [±SD], 1.3 ± 0.54) at hour 10 or day 4. Peripheral CXCL10 levels were higher at treatment hour 10 (P =. 032) and day 2 (P =. 009) in patients with undetectable virus 2 weeks after treatment initiation. Treatment hour 10 (P =. 023) and peak (P =. 034) intrahepatic CXCL10 levels were also higher in these patients. CXCL10 did not distinguish treatment responders from nonresponders. In conclusion, CXCL10 identified very rapid virological response in patients treated with a direct-acting antiviral. Clinical Trials Registration. NCT00892697.

Original language	English
Pages (from-to)	1795-1799
Number of pages	5
Journal	Journal of Infectious Diseases
Volume	211
Issue number	11
DOIs	https://doi.org/10.1093/infdis/jiu807
State	Published - Jun 1 2015

Keywords

CXCL10
HCV
chemokines
liver inflammation

Access to Document

10.1093/infdis/jiu807

Cite this

@article{f2f56c9e9fc04f9691e3a6c7184add1a,

title = "Intrahepatic and peripheral CXCL10 expression in hepatitis C virus-infected patients treated with telaprevir, pegylated interferon, and ribavirin",

abstract = "We assessed peripheral and liver CXCL10 levels in 15 patients treated with telaprevir/pegylated interferon/ribavirin. Induction of peripheral CXCL10 messenger RNA (mRNA) peaked (mean fold-induction [±SD], 3.1 ± 1.9) between treatment hour 6 and day 2, while induction of intrahepatic CXCL10 mRNA peaked (mean fold-induction [±SD], 1.3 ± 0.54) at hour 10 or day 4. Peripheral CXCL10 levels were higher at treatment hour 10 (P =. 032) and day 2 (P =. 009) in patients with undetectable virus 2 weeks after treatment initiation. Treatment hour 10 (P =. 023) and peak (P =. 034) intrahepatic CXCL10 levels were also higher in these patients. CXCL10 did not distinguish treatment responders from nonresponders. In conclusion, CXCL10 identified very rapid virological response in patients treated with a direct-acting antiviral. Clinical Trials Registration. NCT00892697.",

keywords = "CXCL10, HCV, chemokines, liver inflammation",

author = "Marija Zeremski and Dimova, \{Rositsa B.\} and Samantha Benjamin and Penney, \{Marina S.\} and Botfield, \{Martyn C.\} and Talal, \{Andrew H.\}",

year = "2015",

month = jun,

day = "1",

doi = "10.1093/infdis/jiu807",

language = "English",

volume = "211",

pages = "1795--1799",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "11",

}

TY - JOUR

T1 - Intrahepatic and peripheral CXCL10 expression in hepatitis C virus-infected patients treated with telaprevir, pegylated interferon, and ribavirin

AU - Zeremski, Marija

AU - Dimova, Rositsa B.

AU - Benjamin, Samantha

AU - Penney, Marina S.

AU - Botfield, Martyn C.

AU - Talal, Andrew H.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - We assessed peripheral and liver CXCL10 levels in 15 patients treated with telaprevir/pegylated interferon/ribavirin. Induction of peripheral CXCL10 messenger RNA (mRNA) peaked (mean fold-induction [±SD], 3.1 ± 1.9) between treatment hour 6 and day 2, while induction of intrahepatic CXCL10 mRNA peaked (mean fold-induction [±SD], 1.3 ± 0.54) at hour 10 or day 4. Peripheral CXCL10 levels were higher at treatment hour 10 (P =. 032) and day 2 (P =. 009) in patients with undetectable virus 2 weeks after treatment initiation. Treatment hour 10 (P =. 023) and peak (P =. 034) intrahepatic CXCL10 levels were also higher in these patients. CXCL10 did not distinguish treatment responders from nonresponders. In conclusion, CXCL10 identified very rapid virological response in patients treated with a direct-acting antiviral. Clinical Trials Registration. NCT00892697.

AB - We assessed peripheral and liver CXCL10 levels in 15 patients treated with telaprevir/pegylated interferon/ribavirin. Induction of peripheral CXCL10 messenger RNA (mRNA) peaked (mean fold-induction [±SD], 3.1 ± 1.9) between treatment hour 6 and day 2, while induction of intrahepatic CXCL10 mRNA peaked (mean fold-induction [±SD], 1.3 ± 0.54) at hour 10 or day 4. Peripheral CXCL10 levels were higher at treatment hour 10 (P =. 032) and day 2 (P =. 009) in patients with undetectable virus 2 weeks after treatment initiation. Treatment hour 10 (P =. 023) and peak (P =. 034) intrahepatic CXCL10 levels were also higher in these patients. CXCL10 did not distinguish treatment responders from nonresponders. In conclusion, CXCL10 identified very rapid virological response in patients treated with a direct-acting antiviral. Clinical Trials Registration. NCT00892697.

KW - CXCL10

KW - HCV

KW - chemokines

KW - liver inflammation

UR - https://www.scopus.com/pages/publications/84930456996

U2 - 10.1093/infdis/jiu807

DO - 10.1093/infdis/jiu807

M3 - Article

C2 - 25512630

AN - SCOPUS:84930456996

SN - 0022-1899

VL - 211

SP - 1795

EP - 1799

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 11

ER -

Intrahepatic and peripheral CXCL10 expression in hepatitis C virus-infected patients treated with telaprevir, pegylated interferon, and ribavirin

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this